SEC Company Response from Solid Biosciences Inc. (SLDB) (CIK 0001707502) (SLDB) — Jan 22, 2018
Solid Biosciences Inc. (SLDB) (CIK 0001707502)
Date: Jan. 22, 2018 · CIK: 0001707502 · Accession: 0001193125-18-015773
AI Filing Summary & Sentiment
Reasoning
Letter
J.P. Morgan Securities LLC
383 Madison Avenue
New York, New York 10179
Goldman Sachs & Co. LLC
200 West Street
New York, New York 10282-2198
Leerink Partners LLC
299 Park Avenue, 21st Floor
New York, New York 10171
January 22, 2018
United States Securities and Exchange Commission
Division of Corporation Finance
Mail Stop 4720
100 F Street, N.E.
Washington, D.C. 20549
Attn: Ms. Christine Westbrook
Re: Solid Biosciences, LLC
Registration Statement on Form S-1
Registration File No. 333- 222357
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, hereby join in the request of Solid Biosciences, LLC (the “Company”) for acceleration of the effective date of the above-named Registration Statement so that it becomes effective at 3:00 PM, Eastern Time, on January 24, 2018 or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, Proskauer Rose LLP, request by telephone that such Registration Statement be declared effective.
Pursuant to Rule 460 under the Act, we, as representatives of the several underwriters, wish to advise you that we have effected the following distribution of the Company’s Preliminary Prospectus dated January 16, 2018:
(i) Dates of distribution: January 16, 2018 through the date hereof
(ii) Number of prospective underwriters to which the preliminary prospectus was furnished: 5
(iii) Number of prospectuses furnished to investors: approximately: 3,000
(iv) Number of prospectuses distributed to others, including the Company, the Company’s counsel, independent accountants, and underwriters’ counsel: approximately: 255
We, the undersigned, as representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly yours,
J.P. MORGAN SECURITIES LLC
Acting on behalf of itself and the
several underwriters
By:
J.P. MORGAN SECURITIES LLC
By:
/s/ David Ke
Name: David Ke
Title: Vice President
Very truly yours,
GOLDMAN SACHS & CO. LLC
Acting on behalf of itself and the
several underwriters
By:
GOLDMAN SACHS & CO. LLC
By:
/s/ Elizabeth Wood
Name: Elizabeth Wood
Title: Managing Director
Very truly yours,
LEERINK PARTNERS LLC
Show Raw Text
CORRESP 1 filename1.htm CORRESP J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Goldman Sachs & Co. LLC 200 West Street New York, New York 10282-2198 Leerink Partners LLC 299 Park Avenue, 21st Floor New York, New York 10171 January 22, 2018 United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4720 100 F Street, N.E. Washington, D.C. 20549 Attn: Ms. Christine Westbrook Re: Solid Biosciences, LLC Registration Statement on Form S-1 Registration File No. 333- 222357 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, hereby join in the request of Solid Biosciences, LLC (the “Company”) for acceleration of the effective date of the above-named Registration Statement so that it becomes effective at 3:00 PM, Eastern Time, on January 24, 2018 or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, Proskauer Rose LLP, request by telephone that such Registration Statement be declared effective. Pursuant to Rule 460 under the Act, we, as representatives of the several underwriters, wish to advise you that we have effected the following distribution of the Company’s Preliminary Prospectus dated January 16, 2018: (i) Dates of distribution: January 16, 2018 through the date hereof (ii) Number of prospective underwriters to which the preliminary prospectus was furnished: 5 (iii) Number of prospectuses furnished to investors: approximately: 3,000 (iv) Number of prospectuses distributed to others, including the Company, the Company’s counsel, independent accountants, and underwriters’ counsel: approximately: 255 We, the undersigned, as representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. Very truly yours, J.P. MORGAN SECURITIES LLC Acting on behalf of itself and the several underwriters By: J.P. MORGAN SECURITIES LLC By: /s/ David Ke Name: David Ke Title: Vice President Very truly yours, GOLDMAN SACHS & CO. LLC Acting on behalf of itself and the several underwriters By: GOLDMAN SACHS & CO. LLC By: /s/ Elizabeth Wood Name: Elizabeth Wood Title: Managing Director Very truly yours, LEERINK PARTNERS LLC Acting on behalf of itself and the several underwriters By: LEERINK PARTNERS LLC By: /s/ John I. Fitzgerald, Esq. Name: John I. Fitzgerald, Esq. Title: Managing Director